Rigel Pharmaceuticals is one of the biotechnology companies that use this technology in the development of novelty therapeutics. The business is engaged in the creation of treatments for immune diseases and cancers. Additionally, the business also engages in the development of therapeutics for muscle disorders and inflammatory diseases. The focus of the business is the study of intracellular signaling pathways that serve as the basis of the therapeutics they are developing. These pathways are critical in attacking the mechanisms of the disease. It already has several products in its pipeline research and it advances the development of these therapeutics through its own undertaking or through its strong ties with other pharmaceutical companies.
There are two lead products being developed by the company: Fostamatinib and R348. They also have two preclinical programs and two other oncology product candidates. Fostamatinib is being developed as a treatment for two disorders: Thrombocytopenic Purpura and IgAn. Both diseases are categorized as autoimmune diseases. The former is when the immune systems start attacking and destroying the platelets in the blood. IgAn or Immunoglobulin A Nephropathy is an autoimmune disease that severely damages the functions of the kidneys. There are not that many options to treat these diseases. R-348 is being developed as a treatment for dry eyes in patients who are suffering from ocular graft-versus-host disease (GvHD).
It is in San Francisco, California that the business holds its corporate office. It remains publicly traded on the NADAQ and markets its common shares using the symbol RIGL.